HR 6485 · in committee · major
Skinny Labels, Big Savings Act
- healthcare
What this bill does
- This bill protects generic and biosimilar drug makers from patent lawsuits when they seek approval for skinny labels covering only non-patented uses.
- Generic and biosimilar manufacturers are affected, along with patients who use these lower-cost drugs.
- The bill creates a legal safe harbor with no direct federal cost, taking effect upon enactment.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might protecting generic manufacturers from patent lawsuits over skinny labels affect drug development timelines and prices for patients seeking lower-cost alternatives?
- 02
What evidence supports the claim that skinny label protections would increase generic drug availability without reducing incentives for brand-name drug innovation?
- 03
Which stakeholders—patients, manufacturers, or patent holders—would face the greatest risks or benefits if this safe harbor becomes law?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-VA-6
Ben Cline
Citizen cosponsors
0
In Congress
3/ 435
House Reps cosponsoring
Introduced 2025-12-05
Joining the bill
Legislative timeline
2025-12-05 · house · IntroReferral
Referred to the House Committee on the Judiciary.
2025-12-05 · IntroReferral
Introduced in House
2025-12-05 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.